Valuation: Ultragenyx Pharmaceutical Inc.

Market Cap 1.58B 1.42B 1.3B 1.18B 2.21B 150B 2.25B 15.55B 6.24B 79.04B 5.94B 5.81B 249B P/E 2026 *
-4.32x
P/E 2027 * -28.1x
Enterprise Value 1.16B 1.03B 952M 863M 1.61B 110B 1.64B 11.35B 4.56B 57.71B 4.34B 4.24B 182B EV / Sales 2026 *
1.52x
EV / Sales 2027 * 1.05x
Free-Float
96.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ultragenyx Pharmaceutical Inc.

1 day-4.05%
1 week+2.88%
1 month+7.12%
3 months-35.37%
6 months-34.79%
Current year-30.00%
1 week 15.59
Extreme 15.59
17.62
1 month 14.08
Extreme 14.08
17.62
Current year 12.73
Extreme 12.73
36.57
1 year 12.73
Extreme 12.73
39.89
3 years 12.73
Extreme 12.73
60.37
5 years 12.73
Extreme 12.73
89.56
10 years 12.73
Extreme 12.73
179.65
Manager TitleAgeSince
Chief Executive Officer 65 22/04/2010
Director of Finance/CFO 49 16/10/2023
Chief Tech/Sci/R&D Officer 53 01/05/2023
Director TitleAgeSince
Director/Board Member 65 22/04/2010
Director/Board Member 62 01/01/2014
Director/Board Member 66 20/02/2015
Date Insider Type Main position Quantity % Market Cap. Importance
15/9/26 Sell

Controller/Auditor

-1,283 0.0013%
3/9/26 Sell

Controller/Auditor

-161 0.0002%
3/8/26 Sell

General Counsel

-1,900 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
-4.05%+2.88%-53.47%-54.52% 1.58B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.47%+5.60%+36.46%+70.10% 426.35B
Weighted average by Cap. +2.00%+6.60%+50.36%+99.88%

Financials

2026 *2027 *
Net sales 760M 681M 626M 567M 1.06B 72.18B 1.08B 7.47B 3B 37.97B 2.85B 2.79B 120B 997M 893M 821M 744M 1.39B 94.67B 1.42B 9.8B 3.93B 49.8B 3.74B 3.66B 157B
Net income -390M -350M -322M -291M -545M -37.08B -555M -3.84B -1.54B -19.5B -1.47B -1.43B -61.51B -72.28M -64.73M -59.54M -53.95M -101M -6.86B -103M -710M -285M -3.61B -271M -265M -11.38B
Net Debt -427M -382M -352M -319M -596M -40.54B -607M -4.19B -1.68B -21.32B -1.6B -1.57B -67.25B -531M -476M -438M -397M -742M -50.46B -755M -5.22B -2.1B -26.55B -1.99B -1.95B -83.71B
Projected Income Statement - Annual - Ultragenyx Pharmaceutical Inc.
Logo Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.
Employees
1,371
Date Price Change Volume
30/10/26 USD 16.10 -4.05% 2,334,285
29/10/26 USD 16.78 -2.44% 2,803,762
28/10/26 USD 17.20 +2.69% 2,323,533
27/10/26 USD 16.75 +4.17% 4,944,537
26/10/26 USD 16.08 +2.75% 3,023,155
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Ultragenyx Pharmaceutical Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.10USD
Average target price
26.25USD
Spread / Average Target
+63.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ultragenyx Pharmaceutical Inc.
  1. Stock Market
  2. Stocks
  3. RARE Stock